The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Prostate Cancer Diagnostics Market Research Report 2024

Global Prostate Cancer Diagnostics Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1410645

No of Pages : 87

Ask Your Query

Synopsis

The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.

Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.

The global Prostate Cancer Diagnostics market was valued at US$ 13430 million in 2023 and is anticipated to reach US$ 22860 million by 2030, witnessing a CAGR of 7.8% during the forecast period 2024-2030.

Market competition is intense. Genomic Health, Abbott, OPKO, Siemens Healthcare, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. Those key players got about 4% market shares. North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49%. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28%.

This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Diagnostics.

Report Scope

The Prostate Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Prostate Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Prostate Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • OPKO
  • Genomic Health
  • Abbott
  • Beckman Coulter
  • Siemens Healthcare
  • bioMeriux
  • Roche
  • MDx Health
  • DiaSorin
  • Myriad Genetics
  • Ambry Genetics

Segment by Type

  • Tumor Biomarker Tests
  • Imaging
  • Biopsy
  • Other

Segment by Application

  • Age Below 55
  • Age 55-75
  • Age Above 75

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Prostate Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Prostate Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tumor Biomarker Tests
1.2.3 Imaging
1.2.4 Biopsy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Prostate Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Age Below 55
1.3.3 Age 55-75
1.3.4 Age Above 75
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Prostate Cancer Diagnostics Market Perspective (2019-2030)
2.2 Prostate Cancer Diagnostics Growth Trends by Region
2.2.1 Global Prostate Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Prostate Cancer Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Prostate Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Prostate Cancer Diagnostics Market Dynamics
2.3.1 Prostate Cancer Diagnostics Industry Trends
2.3.2 Prostate Cancer Diagnostics Market Drivers
2.3.3 Prostate Cancer Diagnostics Market Challenges
2.3.4 Prostate Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Prostate Cancer Diagnostics Players by Revenue
3.1.1 Global Top Prostate Cancer Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Prostate Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Prostate Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Prostate Cancer Diagnostics Revenue
3.4 Global Prostate Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Prostate Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prostate Cancer Diagnostics Revenue in 2023
3.5 Prostate Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Prostate Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Prostate Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Prostate Cancer Diagnostics Breakdown Data by Type
4.1 Global Prostate Cancer Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Prostate Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
5 Prostate Cancer Diagnostics Breakdown Data by Application
5.1 Global Prostate Cancer Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Prostate Cancer Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Prostate Cancer Diagnostics Market Size (2019-2030)
6.2 North America Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Prostate Cancer Diagnostics Market Size by Country (2019-2024)
6.4 North America Prostate Cancer Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Prostate Cancer Diagnostics Market Size (2019-2030)
7.2 Europe Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Prostate Cancer Diagnostics Market Size by Country (2019-2024)
7.4 Europe Prostate Cancer Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Prostate Cancer Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Prostate Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Prostate Cancer Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Prostate Cancer Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Prostate Cancer Diagnostics Market Size (2019-2030)
9.2 Latin America Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Prostate Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Prostate Cancer Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Prostate Cancer Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Prostate Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Prostate Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 OPKO
11.1.1 OPKO Company Detail
11.1.2 OPKO Business Overview
11.1.3 OPKO Prostate Cancer Diagnostics Introduction
11.1.4 OPKO Revenue in Prostate Cancer Diagnostics Business (2019-2024)
11.1.5 OPKO Recent Development
11.2 Genomic Health
11.2.1 Genomic Health Company Detail
11.2.2 Genomic Health Business Overview
11.2.3 Genomic Health Prostate Cancer Diagnostics Introduction
11.2.4 Genomic Health Revenue in Prostate Cancer Diagnostics Business (2019-2024)
11.2.5 Genomic Health Recent Development
11.3 Abbott
11.3.1 Abbott Company Detail
11.3.2 Abbott Business Overview
11.3.3 Abbott Prostate Cancer Diagnostics Introduction
11.3.4 Abbott Revenue in Prostate Cancer Diagnostics Business (2019-2024)
11.3.5 Abbott Recent Development
11.4 Beckman Coulter
11.4.1 Beckman Coulter Company Detail
11.4.2 Beckman Coulter Business Overview
11.4.3 Beckman Coulter Prostate Cancer Diagnostics Introduction
11.4.4 Beckman Coulter Revenue in Prostate Cancer Diagnostics Business (2019-2024)
11.4.5 Beckman Coulter Recent Development
11.5 Siemens Healthcare
11.5.1 Siemens Healthcare Company Detail
11.5.2 Siemens Healthcare Business Overview
11.5.3 Siemens Healthcare Prostate Cancer Diagnostics Introduction
11.5.4 Siemens Healthcare Revenue in Prostate Cancer Diagnostics Business (2019-2024)
11.5.5 Siemens Healthcare Recent Development
11.6 bioMeriux
11.6.1 bioMeriux Company Detail
11.6.2 bioMeriux Business Overview
11.6.3 bioMeriux Prostate Cancer Diagnostics Introduction
11.6.4 bioMeriux Revenue in Prostate Cancer Diagnostics Business (2019-2024)
11.6.5 bioMeriux Recent Development
11.7 Roche
11.7.1 Roche Company Detail
11.7.2 Roche Business Overview
11.7.3 Roche Prostate Cancer Diagnostics Introduction
11.7.4 Roche Revenue in Prostate Cancer Diagnostics Business (2019-2024)
11.7.5 Roche Recent Development
11.8 MDx Health
11.8.1 MDx Health Company Detail
11.8.2 MDx Health Business Overview
11.8.3 MDx Health Prostate Cancer Diagnostics Introduction
11.8.4 MDx Health Revenue in Prostate Cancer Diagnostics Business (2019-2024)
11.8.5 MDx Health Recent Development
11.9 DiaSorin
11.9.1 DiaSorin Company Detail
11.9.2 DiaSorin Business Overview
11.9.3 DiaSorin Prostate Cancer Diagnostics Introduction
11.9.4 DiaSorin Revenue in Prostate Cancer Diagnostics Business (2019-2024)
11.9.5 DiaSorin Recent Development
11.10 Myriad Genetics
11.10.1 Myriad Genetics Company Detail
11.10.2 Myriad Genetics Business Overview
11.10.3 Myriad Genetics Prostate Cancer Diagnostics Introduction
11.10.4 Myriad Genetics Revenue in Prostate Cancer Diagnostics Business (2019-2024)
11.10.5 Myriad Genetics Recent Development
11.11 Ambry Genetics
11.11.1 Ambry Genetics Company Detail
11.11.2 Ambry Genetics Business Overview
11.11.3 Ambry Genetics Prostate Cancer Diagnostics Introduction
11.11.4 Ambry Genetics Revenue in Prostate Cancer Diagnostics Business (2019-2024)
11.11.5 Ambry Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock